Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole genome transcriptomics of upper extremity veins from end-stage kidney disease patients and non-kidney disease organ donors

ABSTRACT: Whole genome transcriptomics of upper extremity veins from end-stage kidney disease patients and non-kidney disease organ donors

PROVIDER: PRJNA975585 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24709841.fastq.gz	Fastqsanger.gz
	SRR24709842.fastq.gz	Fastqsanger.gz
	SRR24709843.fastq.gz	Fastqsanger.gz
	SRR24709844.fastq.gz	Fastqsanger.gz
	SRR24709845.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 29

Similar Datasets

Whole genome transcriptomics of upper extremity veins from end-stage kidney disease patients and non-kidney disease organ donors

Project description:We report the RNA expression profiles of native veins used for AVF creation and of non-kidney disease veins obtained from organ donors.

2023-09-07 | GSE233264 | GEO

Microarray analysis of mesenteric arteries and veins in Crohn's disease compared to controls from non-IBD samples

Project description:Histology in the mesentery pointed to altered blood vessels. This experiment was designed to define the differences in gene expression in vessels from Crohn's disease versus controls. Crohn's disease was separately evaluated in inflamed (central disease) areas and in adjacent noninflamed areas. Laser capture microdissection was carried out on Carnoy's fixed mesenteric samples, comparing normal arteries or veins with Crohn's inflamed or nonifnlamed arteries or veins.

2015-03-05 | E-GEOD-66545 | biostudies-arrayexpress

Proteomic characteristics of vessels in patients with chronic kidney disease

Project description:In this study, isobaric tags for relative and absolute quantification (ITRAQ) and Q Exactive mass spectrometer were used for non-targeted proteomic profiling of forearm arteries and veins in patients with chronic kidney disease stage 5 (with or without diabetes mellitus, obtained from arteriovenous fistula surgery) and healthy controls (obtained from patients with forearm trauma). Protein identifications were acquired against the Uniport Human database. As a result, 497609 spectra were obtained and 3244 proteins were identified with 96525 matched peptides.

2019-06-24 | PXD010883 | Pride

In-transit extremity melanoma III

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion or isolated limb perfusion. Gene expression profiles were obtained from 21 lesions across 19 patients and evaluated for expression that correlated with response to melphalan isolated limb infusion. Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD; not evaluable - n.e.

2011-12-22 | E-GEOD-34599 | biostudies-arrayexpress

The proteome of personalized tissue-engineered veins

Project description:Tissue-engineered veins were generated by reconditioning decellularized veins from both human and pig with whole-blood from respective species. Decellularized human vena femoralis from three donor were reconditioned with human whole blood from four donors. In addition, decellularized pig vena cava from three donors were reconditioned with pig whole blood from three different donors. The proteomes of the tissue-engineered veins were investigated applying the TMT-based proteomics to explore differences between species, regarding the gain of biological material by the reconditioning process.

2024-05-21 | PXD044069 | Pride

Trancription profling of In-transit extremity melanoma II lesions

Project description:An evaluation of biopsies from patients with in-transit extremity melanoma who have been treated with melphalan in the setting of isolated limb infusion Gene expression profiles were obtained from 52 lesions across 28 patients and evaluated for expression values that correlated with response to melphalan isolated limb infusion Chemotherapy response analysis: complete response - CR; partial response - PR; stable disease - SD; progressive disease - PD. 52 samples.

2010-03-09 | E-GEOD-19293 | biostudies-arrayexpress

In-transit extremity melanoma I

Project description:An evaluation of multifocal lesions from patients with in-transit extremity melanoma to determine if all lesions from a patient harbor homogeneous patterns of gene expression Gene expression profiling studies can help guide treatment for cancer patients by providing tools in the form of gene-expression signatures to characterize a tumor in terms of underlying biology, predicted response to therapy, metastatic progression and/or recurrence. The utility of gene signatures for defining therapeutic strategies in the treatment of extremity in-transit melanoma will be dependent on the genetic relationship between the multifocal lesions typically present in this disease and the extent to which a single lesion is representative of residual tumor burden. Using microarray-based gene expression profiling we examined 43 in-transit melanoma lesions across 17 patients with multifocal disease to determine whether one lesion could accurately characterize the underlying biology and genetic profile of a patient's tumor. Principal component analysis, unsupervised hierarchical clustering, one-way analysis of variance (ANOVA) and gene signatures predictive of chemosensitivity and oncogenic pathway activation showed gene expression patterns to be highly similar (p-values: <0.006; average r = 0.979) between lesions from a single patient but to be significantly different across patients (p<0.05). These findings demonstrate that individual melanoma tumor nodules in patients with multifocal disease are genetically similar and a single lesion can be used to predict response to chemotherapy, evaluate the activation status of oncogenic signaling pathways and characterize other aspects of the biology of an individual patient's disease. These results will facilitate the utilization of gene expression profiling in clinical trials of targeted therapy in melanoma allowing for more rational identification of candidates for specific therapies. Keywords: Disease state analysis

2008-10-30 | GSE10282 | GEO

Bypass and diabetic kidney disease

Project description:Bypass and diabetic kidney disease

| PRJNA481952 | ENA

In-transit extremity melanoma II

2010-02-26 | GSE19293 | GEO

Kidney Transcriptome and Polycystic Kidney Disease Genes in Zebrafish

Project description:Kidney Transcriptome and Polycystic Kidney Disease Genes in Zebrafish

| PRJNA932807 | ENA